SEC Filings

Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT^® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

Filing date	Form	Description	View
Nov 17, 2021	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-21-010209.pdf 0001179110-21-010209.rtf 0001179110-21-010209.xls
Nov 17, 2021	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-21-010218.pdf 0001179110-21-010218.rtf 0001179110-21-010218.xls
Nov 09, 2021	8-K	Report of unscheduled material events or corporate event	View HTML 0001104659-21-136034.pdf 0001104659-21-136034.rtf 0001104659-21-136034.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Nov 05, 2021	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-21-009894.pdf 0001179110-21-009894.rtf 0001179110-21-009894.xls
Nov 03, 2021	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-21-009821.pdf 0001179110-21-009821.rtf 0001179110-21-009821.xls
Nov 03, 2021	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-21-009819.pdf 0001179110-21-009819.rtf 0001179110-21-009819.xls
Oct 28, 2021	8-K	Report of unscheduled material events or corporate event	View HTML 0001104659-21-130731.pdf 0001104659-21-130731.rtf 0001104659-21-130731.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Oct 28, 2021	10-Q	Quarterly report which provides a continuing view of a company's financial position	View HTML 0001558370-21-013719.pdf 0001558370-21-013719.rtf 0001558370-21-013719.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Oct 19, 2021	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-21-009515.pdf 0001179110-21-009515.rtf 0001179110-21-009515.xls
Oct 07, 2021	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-21-009297.pdf 0001179110-21-009297.rtf 0001179110-21-009297.xls

Investors & Media

Transformative science, targeted medicines

SEC Filings

Pagination